Navamedic ASA: Double Digit Growth in the 3rd Quarter, 2025
Navamedic ASA (OSE: NAVA), a Nordic pharma company, reported revenues of NOK 138.9 million in the third quarter of 2025, a 12.9% increase from the same period in 2024.
Gross margin improved to 37.5%, compared to 37.1% in Q3 2024. Adjusted EBITDA amounted to NOK 11.3 million, up from NOK 8.6 million in 2024.
The revenue growth was driven by increases in all three business areas, including the Rx business area, which generated NOK 10.6 million in revenues from the dne business.
No specific quotes available in the given text.
Author's summary: Navamedic ASA reports double-digit growth in Q3 2025.